We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer.
- Authors
Hongxia ZHANG; Jinsheng GAO; Wei GUO; Bo YU; Haitao YANG; Yutao LIU
- Abstract
Background and objective Dabrafenib+Trametinib/Dabrafenib targeted therapy has been approved for V-RAF murine sarcoma viral oncogene homolog B1 with amino acid substitution for valine at position 600 (BRAF V600E) in lung cancer patients, however, the targeted therapy strategy for lung cancer patients with BRAF non-V600E mutations has not been determined yet. This study intends to explore the efficacy of targeted therapy for BRAF non-V600E mutant lung cancer, and provide a reference for clinical treatment. Methods Computer search of PubMed, Cochrane Library, Embase, Web of Science, Clinicaltrials.gov, CBM, CNKI, Wanfang database. Collect the relevant literature relevant on the targeted therapy of BRAF non-V600E mutant lung cancer, and conduct a descriptive analysis of the included literature. Results There were 10 articles that met the inclusion criteria, including 3 cohort studies and 7 case reports. 18 patients with BRAF non-V600E mutant lung cancer were ineffective to vermurafenib; 1 patient obtained partial response (PR) after applying vermurafenib, 5 patients did not respond to BRA.F inhibitors; 9 patients showed a potential clinical benefit rate of 34% after monotherapy with trametinib; 7 patients have different degrees of benefit from dabrafenib and trametinib on progression-free survival (PFS); 1 patient is effective to sorafenib. Conclusion At present, there is no standard treatment specification for BRAF non-V600E mutation targeted therapy. The challenge lies in the heterogeneous mutation of BRAF gene. Different mutation types respond differently to targeted therapy. In addtion, real-world research evidence is scarce, so it is necessary to carry out further large-sample high-quality research to provide reference for clinical practice.
- Subjects
ONLINE information services; MEDICAL databases; INFORMATION storage &; retrieval systems; MEDICAL information storage &; retrieval systems; GENETIC mutation; PROTEIN kinase inhibitors; SYSTEMATIC reviews; LUNG tumors; TREATMENT effectiveness; SORAFENIB; MEDLINE; PROGRESSION-free survival
- Publication
Chinese Journal of Lung Cancer, 2022, Vol 25, Issue 2, p86
- ISSN
1009-3419
- Publication type
Article
- DOI
10.3779/j.issn.1009-3419.2021.101.51